New skin cell transplant combo aims to restore color in white patches
NCT ID NCT07662915
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two surgical techniques to treat stable white patches on the skin that are not caused by vitiligo. Both methods involve transplanting the patient's own skin cells, followed by laser therapy to boost color return. Twenty-two adults will each receive both treatments on different patches to see which works better and is safer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Melanocyte keratinocyte transplantation procedure (MKTP) and 308-nm excimer laser
- What this could lead to
- If successful, this could point toward a better surgical treatment for stable white patches not caused by vitiligo, improving skin color matching and repigmentation.
- What could go wrong
- This is a very small early study with only 22 participants, so results may not apply to everyone. The procedures involve surgery and laser, which carry risks like infection or scarring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 22 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 to 60 years. * Clinically diagnosed stable non-vitiligo leukoderma. * Stable lesion(s) for at least 6 months with no progression. * Inadequate response to conventional medical therapy. * Presence of two comparable lesions * Willingness to participate and provide written informed consent. Exclusion Criteria: * Vitiligo or suspected active vitiligo. * History of keloid or hypertrophic scar formation. * Active infection at donor or recipient sites. * Bleeding disorders or anticoagulant therapy that cannot be safely discontinued. * Pregnancy or lactation. * Immunosuppression or uncontrolled systemic disease. * Inability to comply with follow-up visits. * Unrealistic expectations regarding treatment outcome.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Leukoderma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.